Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Prescribing costs jump in England

New report finds that asthma and diabetes drugs the most costly to the NHS

- PMLiVE

FDA clears Advair follow up Breo for asthma

But respiratory drug given the thumbs up for adults only

- PMLiVE

Ariad founder Harvey Berger to retire as CEO and chairman

Effective from December 31 or upon finding of successor

Webinar recording: The storytelling method that works for e-detailing

If you can involve healthcare professionals in a story, they will be more open to your arguments.

Anthill Agency

- PMLiVE

New-look Directory from PMGroup launches

Fresh design and updated content shapes the publication’s evolution

- PMLiVE

Prostate cancer treatment market to treble to £8.2bn by 2023

But GlobalData predict growth could be hampered by patent loss for Zytiga

- PMLiVE

Eylea growth closes the gap with Lucentis

Bayer/Regeneron’s drug eye disease drug set for blockbuster status

- PMLiVE

GSK found UK’s drug pricing changes a tough sell

Firm's chief executive met with the government to question the last PPRS update

- PMLiVE

Kythera bags FDA approval for double chin therapy

Comes as cosmetics industry sees major growth

- PMLiVE

Harvoni sales rocket in first quarter

Gilead’s new hepatitis C pill generates stellar revenue

- PMLiVE

Good Relations appoints Louise Veale to consumer health team

She joins as an associate director and will report to Kelly Blaney

- PMLiVE

FDA panel backs Amgen’s T-Vec for melanoma

Approved by a panel of 22 to one despite questions on its impact on survival

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links